Industry news that matters to you.  Learn more

Regulus Achieves All Research Milestones in Collaboration with Biogen to Identify microRNA Biomarkers for Multiple Sclerosis

Reading time: 2 minutes

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has earned a fourth milestone payment in its collaboration with Biogen (NASDAQ: BIIB) related to progress in the companies’ research collaboration to identify microRNAs as biomarkers for multiple sclerosis (“MS”). To earn the milestone, Regulus’ microMarkersSM division used its robust technology platform and bioinformatics expertise to analyze the treatment effects of a Biogen relapsing MS drug on circulating microRNA profiles previously identified by Regulus.

“Our partnership with Biogen is one example of how Regulus microMarkersSM is researching the role and potential of microRNAs as biomarkers for numerous diseases. We’re excited to have identified a promising microRNA biomarker for MS, which we believe was a critical step to understand how microRNAs may change response to drug treatment,” said Paul Grint, M.D., President and CEO of Regulus. “We’re excited to have realized the full potential of the collaboration, and through this work, we’re hopeful that Regulus’ microMarkersSM technology and bioinformatics expertise can improve understanding of multiple sclerosis.”

Regulus and Biogen began their collaboration in August 2012 and expanded their research in August 2014 to identify potential microRNA biomarkers in MS. Under the scope of the agreements, Regulus has realized the full potential of the collaboration and has earned $3.7 million in payments from Biogen. Following achievement of the final milestone, the scope of the research to be performed under the current collaboration agreement has now concluded.

Source: PR Newswire